In this presentation Dr. Lynn Webster, Vice President of Scientific Affairs (Early Development Services), and Michael Marschler, Director of Safety and Risk Management, will discuss how pharmacogenetics can be integrated in clinical trials. The speakers will also outline post-marketing settings to achieve a personalized therapy and how considering missing information (potential risk(s)) of genomic variations can help to identify risk minimization measures to greatly reduce the risk of side effects and significantly increase the therapeutic benefit to the patients.
Not sure if you want to exhibit at or attend the Pharmacogenetics in Pain Management and the Use of Pharmacogenomics Methodologies in the Pharmacovigilance Evaluation of Medicinal Products? See the panels below to get the information you need to make an informed decision.
|Conference/Event Dates:||10/31/2016 - 10/31/2016|
|Primary Industry:||Clinical Pharmacology|
|Other Industries:||Clinical Pharmacology, Professional Healthcare|
|Audience:||"C-Level" Executives - CSO/CMO
Drug Developers in the CNS/Pain/Addiction Therapy fields
Heads of Global Clinical Development
Patient Recruitment and Retention professionals
Senior Physicians/ Prescribers of opioid medications
Clinical Trial Planning and Optimization
|Booth Size||Booth Cost||Available Amenities|
|Marketing Vehicles Allowed:||n/a|
|Other Booth Sizes Available: n/a|
How do I show up here?
Add a note here, it is only visible by you.